Table 1 Baseline patient characteristics.

Age (years): median (range)

75(57–86)

71(42–81)

0.09

Sex (n): Male/Female (%)

22(71.0)/9(29.0)

28(75.7)/9(24.3)

0.66

Height (m): median (range)

1.57(1.36–1.74)

1.57(1.34–1.76)

0.84

Body weight (kg): median (range)

61.2(43.0–86.5)

57.4(34.9–88.8)

0.30

BMI (kg/m²): median (range)

25.8(17.8–31.8)

24.0(16.4–32.0)

0.28

Recurrence (n): Yes/No (%)

17(54.8)/14(45.2)

27(73.0)/10(27.0)

0.12

Performance status (n): 0/1/2/3 (%)

21(67.7)/10(32.3)

22(59.5)/15(40.5)

0.48

Etiology (n): HBV/HCV/NBNC (%)

2(6.5)/18(58.1)/11(35.5)

2(5.4)/12(32.4)/23(62.2)

0.08

Liver condition (n): CH/LC (%)

8(25.8)/23(74.2)

5(13.5)/32(86.5)

0.23

Child-Pugh classification (n): A/B (%)

21(67.7)/10(32.3)

32(86.5)/5(13.5)

0.15

eGFR (n): >60/≤60 (%)

21(67.7)/10(32.3)

28(75.7)/9(24.3)

0.08

Diabetes (n): Yes/No (%)

0(0.0)/31(100.0)

26(70.3)/11(29.7)

< 0.01

Taking antipsychotic drugs (n): Yes/No (%)

0(0.0)/31(100.0)

2(5.4)/35(94.6)

0.50

Taking antiepileptic drugs (n): Yes/No (%)

0(0.0)/31(100.0)

1(2.7)/36(97.3)

> 0.99

Taking benzodiazepines (n): Yes/No (%)

2(6.5)/29(93.5)

5(13.5)/32(86.5)

0.44

AFP (ng/ml): median (range)

8(2–8953)

5(2–2722)

0.54

DCP (mAU/mL): median (range)

76(8–15700)

77(14–10048)

0.76

Maximum tumor size (n): < 3 cm/≥ 3 cm (%)

12(38.7)/19(61.3)

15(40.5)/22(59.5)

0.88

Number of tumors (n): ≤3/≥4 (%)

24(77.4)/7(22.6)

27(73.0)/10(27.0)

0.67

TMN staging LCSGJ 6th (n): I /II /III (%)

2(6.5)/15(48.4)/14(45.2)

4(10.8)/17(45.9)/16(43.2)

0.82

Cisplatin dosage (n): < 50 mg/≥ 50 mg (%)

15(48.4)/16(51.6)

22(59.5)/15(40.5)

0.36

Embolization of hepatic segment (n): < 2/≥ 2 (%)

17(54.8)/14(45.2)

20(54.1)/17(45.9)

0.95